TOP AGO TUMOR SECRETS

In summary, throughout the last ten years by far the most remarkable benefit is attained in HER2/neu-overexpressing MBC. Introduction of bevacizumab like a VEGF-directed focused treatment remains a difficulty on debate. A number of the novel therapeutics on the breast cancer armamentarium resulted in prolongation of survival for patients with MBC.